

What Is Clinical Utility and Why Should We Care?

LJ Lesko¹, I Zineh¹ and S-M Huang¹

This issue of *Clinical Pharmacology & Therapeutics* addresses the complexities and challenges of defining and demonstrating clinical utility in the era of personalized medicine. "Utility" is a term that is ubiquitously used in fields ranging from economics to medicine. Broadly speaking, utility is a measure of the personal benefit that someone has from an intervention, outcome, product, or process. "Clinical utility" is a term that is widely used in medicine to describe the relevance and usefulness of an intervention in patient care. Despite general agreement that clinical utility assessments are multidimensional and may include economic, clinical, and/or humanistic domains, there is no consensus on its definition or how to robustly demonstrate it to the satisfaction of multiple stakeholders.

The individualization of a treatment or an intervention depends on the interplay among intrinsic (i.e., patient-specific) and extrinsic (i.e., environmental) factors.¹ In particular, the use of personal genetic or other biomarker information for the purpose of stratifying patient populations for different dosing and/or treatment strategies, enriching clinical trials,² or identifying patients at risk for adverse events has been postulated as a mechanism by which better health outcomes and lower health-care costs

could be achieved. Despite this promise, many feel that few personalized treatments or interventions have achieved widespread clinical adoption, i.e., have had their clinical utility demonstrated to the satisfaction of health-care providers, third-party payers, and other stakeholders.

Stakeholders in personalized medicine want to know whether genetic tests are valid and useful. The accuracy of a genetic test is evaluated by measuring its analytical and clinical validity. The usefulness of a genetic test is typically evaluated by its clinical utility in medical practice. The issue of clinical utility has been said to be of central importance to personalized medicine.³

The question of evidence generation to support clinical utility

Clinical utility is often test-, drug-, and context-dependent, and it is rarely easily quantified. In the context of a drug-test pair, clinical utility has historically been a composite measure of benefit, risk, and perceived value in medical decision making. Clinical utility is frequently a matter of judgment depending on a stakeholder's perspective of the supporting evidence.

The major questions in the current dialogue regarding the generation of evidence to demonstrate clinical utility are (1) what is the minimum threshold of

¹Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Correspondence: L Lesko (lawrence.lesko@fda.hhs.gov), I Zineh (issam.zineh@fda.hhs.gov), or S-M Huang (shuang@fda.hhs.gov)
doi:10.1038/cpt.2010.229

Clinical Pharmacology in Psychiatry from Molecular Studies to Clinical Reality. Edited by S. G. Dhal and L. F. Gram. pp. DMClinical Pharmacology in Psychiatry: From Molecular Studies to Clinical Reality Kindle CPYJ6AVPCC. Clinical Pharmacology in Psychiatry: From. Molecular.Share to: Clinical Pharmacology in Psychiatry: From Molecular Studies to Clinical Reality / edited by Svein G. View the summary of this work. Bookmark.Clinical Pharmacology in Psychiatry: From Molecular Studies to Clinical. Reality (Psychopharmacology Series). This volume collects the invited lectures.Clinical pharmacology in psychiatry: from molecular studies to clinical realities. Camp. Biochem. Physiol. Vol. 96A,No. 2,pp, Pergamon Press plc.clinical pharmacology in psychiatry from molecular studies to clinical reality psychopharmacology series softcover reprint of the original 1st ed edition.presented at the 5th international meeting on clinical pharmacology in psychiatry molecular studies to clinical reality psychopharmacology series clinical.clinical pharmacology in psychiatry from molecular studies to clinical reality psychopharmacology series. Education WorldBook Center. WorldBook ID ceRead Book Online Now malizair-ulm.com?book=XDownload Clinical Pharmacology in Psychiatry: From Molecular Studies to Clinical Reality.Clinical Pharmacology In Psychiatry From Molecular Studies To Clinical Reality - In this site is not the thesame as a solution calendar you purchase in a.Clinical Pharmacology in Psychiatry: From Molecular Studies to Clinical Reality. The chapters of this volume illustrate the continuity from experimental.From Molecular Studies to Clinical Reality Svein G. Dahl, Lars F. Gram. Clinical Pharmacology in Psychiatry From Molecular Studies to Clinical Reality Edited by .Brosen K, Gram LF (b) Pharmacokinetics of the selective serotonin reuptake pharmacology in psychiatry from molecular studies to clinical reality.Request PDF on ResearchGate Clinical Pharmacology in Psychiatry: Clinical Pharmacology in Psychiatry: From Molecular Studies to Clinical Reality.CLINICAL. PHARMACOLOGY. IN. PSYCHIATRY. FROM. MOLECULAR. STUDIES TO CLINICAL REALITY PDF -. Search results, Pathophysiology of Disease.Clinical Pharmacology In Psychiatry From Molecular Studies To Clinical Reality - In this site is not the similar as a answer manual you purchase in a photograph.clinical pharmacology in psychiatry bridging the experimental therapeutic gap from molecular studies to clinical reality by with rakuten kobo this volume.

[\[PDF\] Mosbys 2007 Dental Drug Consult](#)

[\[PDF\] Five Denials On Merlins Grave: A Poem With Annotations](#)

[\[PDF\] Butterflies And Moths: A Companion To Your Field Guide](#)

[\[PDF\] The Britons Quest For Freedom: Our Unfinished Journey](#)

[\[PDF\] German Immigration And Servitude In America, 1709-1920](#)

[\[PDF\] Law And Development In East And Southeast Asia](#)

